Literature DB >> 1380007

Immunodominant regions within the hepatitis C virus core and putative matrix proteins.

M Sällberg1, U Rudén, B Wahren, L O Magnius.   

Abstract

The complete amino acid sequences of hepatitis C virus (HCV) core (residues 1 to 115) and putative matrix (residues 116 to 190) proteins were synthesized as 18-residue-long peptides with an 8-amino-acid overlap. The peptides were assayed with 50 human serum samples with antibodies to HCV (anti-HCV) and 46 serum samples without anti-HCV, as determined by several commercial assays. Immunodominant regions were defined within residues 1 to 18, 11 to 28, 21 to 38, 51 to 68, and 101 to 118. The peptides that covered these regions were recognized by 40 of 50 (80%), 42 of 50 (84%), 36 of 50 (72%), 34 of 48 (68%), and 36 of 48 (72%) of the anti-HCV positive serum samples, respectively. Two anti-HCV negative serum samples were each repeatedly reactive with one peptide, but both were found to be negative by confirmatory anti-HCV assays. Four serum samples that were confirmed to be positive for anti-HCV in commercial assays did not recognize any of the peptides that cover the HCV core-matrix regions. Ninety-two percent of anti-HCV-positive serum samples reacted with a combination of peptides covering residues 1 to 18 and 11 to 28. Testing of peptides that contain the reported genotypic variations of the HCV core within the regions at residues 1 to 18, 51 to 68, and 101 to 118 showed that a change from Thr-110 to Asn-110 decreased the reactivities of eight serum samples. In conclusion, we found that human antibodies to the HCV core-matrix protein(s) are mainly directed to linear determinants and can easily be reproduced by using short synthetic peptides. We also found that such antibodies develop in more than 90% of HCV-infected people.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380007      PMCID: PMC265429          DOI: 10.1128/jcm.30.8.1989-1994.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers.

Authors:  K Takeuchi; Y Kubo; S Boonmar; Y Watanabe; T Katayama; Q L Choo; G Kuo; M Houghton; I Saito; T Miyamura
Journal:  Nucleic Acids Res       Date:  1990-08-11       Impact factor: 16.971

2.  Hepatitis C virus antibody in HIV-1 infected Ugandan mothers.

Authors:  J B Jackson; L Guay; J Goldfarb; K Olness; C Ndugwa; F Mmiro; P Kataaha; J P Allain
Journal:  Lancet       Date:  1991-03-02       Impact factor: 79.321

3.  Specificity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regions.

Authors:  L Mimms; D Vallari; L Ducharme; P Holland; I K Kuramoto; J Zeldis
Journal:  Lancet       Date:  1990 Dec 22-29       Impact factor: 79.321

4.  Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins.

Authors:  M Sällberg; U Rudén; L O Magnius; E Norrby; B Wahren
Journal:  Immunol Lett       Date:  1991-09       Impact factor: 3.685

5.  Antibodies to hepatitis C virus in Italian blood donors.

Authors:  G Sirchia; A Bellobuono; A Giovanetti; M Marconi
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

6.  Human and monoclonal antibodies to hepatitis B core antigen recognise a single immunodominant epitope.

Authors:  R B Ferns; R S Tedder
Journal:  J Med Virol       Date:  1986-06       Impact factor: 2.327

7.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

8.  Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen.

Authors:  M Sällberg; U Rudén; L O Magnius; H P Harthus; M Noah; B Wahren
Journal:  J Med Virol       Date:  1991-04       Impact factor: 2.327

9.  Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.

Authors:  N Ogata; H J Alter; R H Miller; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

10.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

View more
  12 in total

1.  Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame.

Authors:  J L Walewski; T R Keller; D D Stump; A D Branch
Journal:  RNA       Date:  2001-05       Impact factor: 4.942

2.  IgG1 anti-P2 as a marker of response to interferon in patients with chronic hepatitis C.

Authors:  M Hirayama; T Maruyama; H Mitsui; H Maekawa; H Yamada; N Hashimoto; K Koike; S Kimura; K Yasuda; S Iino; J Green
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

3.  Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein.

Authors:  M Sällberg; U Rudén; B Wahren; L O Magnius
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

4.  Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1.

Authors:  K Siemoneit; M da S Cardoso; K Koerner; A Wölpl; B Kubanek
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

5.  Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein.

Authors:  A Yoshikawa; T Tanaka; Y Hoshi; N Kato; K Tachibana; H Iizuka; A Machida; H Okamoto; M Yamasaki; Y Miyakawa
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

6.  Sequence analysis of the core gene of 14 hepatitis C virus genotypes.

Authors:  J Bukh; R H Purcell; R H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

Review 7.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

8.  Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the host-derived GOR protein.

Authors:  Z X Zhang; M Chen; K Wallhagen; J Trojnar; L O Magnius; B Wahren; M Sällberg
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

9.  Levels of hepatitis C virus (HCV) RNA in serum and their relationship to levels of immunoglobulin M and G antibodies against HCV core protein.

Authors:  M Chen; A Sönnerborg; M Sällberg
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

10.  Antigenic structure of the complete nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV): anti-HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection.

Authors:  Z X Zhang; M Chen; A Sönnerborg; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.